查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1317919

癫痫药物市场：按产品类型、分销管道 - 全球预测 2023-2030

Epilepsy Drug Market by Product Type, Distribution Channel - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

全球抗癫痫药物市场预计将以7.07%的复合年增长率大幅成长，到2023年达到45.5177亿美元，到2030年将达到惊人的73.5289亿美元。

FPNV定位矩阵

FPNV定位矩阵对于评估全球癫痫药物市场至关重要。透过检查业务策略和产品满意度的关键指标，我们对供应商进行全面评估，使您能够根据您的特定需求做出明智的资讯。这种进阶分析将供应商分为四个像限，并取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市占率分析

市场占有率分析可以深入了解供应商在特定市场领域的当前地位。比较供应商对总收入、基本客群和其他关键指标的贡献，可以帮助公司更好地了解他们在争夺市场份额时的表现以及面临的情况。该分析还揭示了特定行业的竞争程度、累积和合併的优势以及研究基准年的合併特征。

本报告提供了以下几点见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开发：提供有关利润丰厚的新兴市场的详细资讯，并分析其在成熟市场的渗透率。

3. 市场多元化：提供有关新产品发布、未开发地区、最新发展和投资的详细资讯。

4.市场趋势：全面了解COVID-19、俄罗斯-乌克兰衝突和高通膨的累积影响。

5.竞争评估与资讯：对主要企业的市场占有率、策略、产品、认证、法规状况、专利状况、製造能力等进行综合评估。

6. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告回答了以下问题：

1.全球癫痫药物市场规模及预测为何？

2.在预测期内，COVID-19对全球癫痫药物市场的阻碍因素与影响有哪些？

3. 在预测期内，全球癫痫药物市场需要投资哪些产品/细分市场/应用/领域？

4.你们在全球癫痫药物市场的竞争策略是什么？

5.全球癫痫药物市场的技术趋势和法律规范是什么？

6.全球癫痫药物市场主要厂商的市占率为何？

7. 哪些型态和策略性倡议被认为适合进入全球癫痫药物市场？

目录

第1章前言

第2章调查方法

第3章执行摘要

第4章市场概况

第5章市场洞察

  • 市场动态
    • 促进因素
      • 癫痫盛行率增加
      • 神经系统疾病、产伤及交通伤害的发生率增加
      • 政府加大投入与支持
    • 抑制因素
      • 缺乏基础设施和癫痫治疗
    • 机会
      • 抗惊厥药物的法规批准增加
      • 协作渗透和产品发布活动
    • 任务
      • 与药物相关的副作用
  • 市场趋势
  • COVID-19 的累积影响
  • 俄罗斯-乌克兰衝突的累积影响
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法律规范
  • 客户客製化

第6章癫痫药物市场：依产品类型

  • 第一代医学
    • 乙舒酰亚胺
    • 奥卡西平
    • 苯妥英
  • 第二代医学
    • 非氨酯
    • 拉莫三嗪
    • 托吡酯
  • 第三代医学
    • 醋酸艾斯利卡西平
    • 拉科酰胺
    • 拉非酰胺

第7章癫痫药物市场：按分销管道

  • 医院药房
  • 药局

第8章北美与南美癫痫药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第9章亚太癫痫药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第10章欧洲、中东和非洲癫痫药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第11章竞争形势

  • FPNV定位矩阵
  • 市占率分析：主要企业
  • 竞争情境分析：主要企业

第12章上市公司名单

第13章附录

  • 讨论指南
  • 关于许可证和定价
Product Code: MRR-4348D129FAC4

The Global Epilepsy Drug Market is forecasted to grow significantly, with a projected USD 4,551.77 million in 2023 at a CAGR of 7.07% and expected to reach a staggering USD 7,352.89 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Epilepsy Drug Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Epilepsy Drug Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Product Type, market is studied across First-Generation Drugs, Second-Generation Drugs, and Third-Generation Drugs. The First-Generation Drugs is further studied across Ethosuximide, Oxcarbazepine, and Phenytoin. The Second-Generation Drugs is further studied across Felbamate, Lamotrigine, and Topiramate. The Third-Generation Drugs is further studied across Eslicarbazepine Acetate, Lacosamide, and Ralfinamide. The Third-Generation Drugs is projected to witness significant market share during forecast period.

Based on Distribution Channel, market is studied across Hospital Pharmacy and Pharmacy Stores. The Hospital Pharmacy is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.74% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Epilepsy Drug Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Epilepsy Drug Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Epilepsy Drug Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Epilepsy Drug Market?

4. What is the competitive strategic window for opportunities in the Global Epilepsy Drug Market?

5. What are the technology trends and regulatory frameworks in the Global Epilepsy Drug Market?

6. What is the market share of the leading vendors in the Global Epilepsy Drug Market?

7. What modes and strategic moves are considered suitable for entering the Global Epilepsy Drug Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Epilepsy Drug Market, by Product Type, 2022 vs 2030
  • 4.3. Epilepsy Drug Market, by Distribution Channel, 2022 vs 2030
  • 4.4. Epilepsy Drug Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalences of epilepsy
      • 5.1.1.2. Rising incidence of neurological disorders, birth-related injuries, and traffic injuries
      • 5.1.1.3. Rising investment and support from the government
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of infrastructure and scarcity of treatment for epilepsy
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising drug approvals of anticonvulsant drugs from regulatory bodies
      • 5.1.3.2. Penetration of collaboration and product launch activities
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated with the drugs
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Epilepsy Drug Market, by Product Type

  • 6.1. Introduction
  • 6.2. First-Generation Drugs
    • 6.2.1. Ethosuximide
    • 6.2.2. Oxcarbazepine
    • 6.2.3. Phenytoin
  • 6.3. Second-Generation Drugs
    • 6.3.1. Felbamate
    • 6.3.2. Lamotrigine
    • 6.3.3. Topiramate
  • 6.4. Third-Generation Drugs
    • 6.4.1. Eslicarbazepine Acetate
    • 6.4.2. Lacosamide
    • 6.4.3. Ralfinamide

7. Epilepsy Drug Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Hospital Pharmacy
  • 7.3. Pharmacy Stores

8. Americas Epilepsy Drug Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Epilepsy Drug Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Epilepsy Drug Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player

12. List of Company Mentioned

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. EPILEPSY DRUG MARKET RESEARCH PROCESS
  • FIGURE 2. EPILEPSY DRUG MARKET SIZE, 2022 VS 2030
  • FIGURE 3. EPILEPSY DRUG MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2022 VS 2030 (%)
  • FIGURE 5. EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2030 (%)
  • FIGURE 6. EPILEPSY DRUG MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 7. EPILEPSY DRUG MARKET DYNAMICS
  • FIGURE 8. EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 9. EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. UNITED STATES EPILEPSY DRUG MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. ASIA-PACIFIC EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. EUROPE, MIDDLE EAST & AFRICA EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. EPILEPSY DRUG MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 15. EPILEPSY DRUG MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. EPILEPSY DRUG MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. EPILEPSY DRUG MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 5. EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 6. EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. EPILEPSY DRUG MARKET SIZE, BY ETHOSUXIMIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. EPILEPSY DRUG MARKET SIZE, BY OXCARBAZEPINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. EPILEPSY DRUG MARKET SIZE, BY PHENYTOIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 11. EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. EPILEPSY DRUG MARKET SIZE, BY FELBAMATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. EPILEPSY DRUG MARKET SIZE, BY LAMOTRIGINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. EPILEPSY DRUG MARKET SIZE, BY TOPIRAMATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 16. EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. EPILEPSY DRUG MARKET SIZE, BY ESLICARBAZEPINE ACETATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. EPILEPSY DRUG MARKET SIZE, BY LACOSAMIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. EPILEPSY DRUG MARKET SIZE, BY RALFINAMIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 21. EPILEPSY DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. EPILEPSY DRUG MARKET SIZE, BY PHARMACY STORES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES EPILEPSY DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. CHINA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. INDIA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. INDIA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. INDONESIA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. INDONESIA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. JAPAN EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. JAPAN EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 83. JAPAN EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. MALAYSIA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. MALAYSIA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 88. MALAYSIA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. PHILIPPINES EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. PHILIPPINES EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 93. PHILIPPINES EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. SINGAPORE EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. SINGAPORE EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 98. SINGAPORE EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. SOUTH KOREA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. SOUTH KOREA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 103. SOUTH KOREA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. TAIWAN EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. TAIWAN EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 108. TAIWAN EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. THAILAND EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. THAILAND EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 113. THAILAND EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. VIETNAM EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. VIETNAM EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 118. VIETNAM EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. DENMARK EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. DENMARK EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 129. DENMARK EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. EGYPT EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. EGYPT EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 134. EGYPT EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. FINLAND EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. FINLAND EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 139. FINLAND EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. FRANCE EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. FRANCE EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 144. FRANCE EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. GERMANY EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. GERMANY EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 149. GERMANY EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. ISRAEL EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. ISRAEL EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 154. ISRAEL EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. ITALY EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. ITALY EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 159. ITALY EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. NETHERLANDS EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. NETHERLANDS EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 164. NETHERLANDS EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 167. NIGERIA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. NIGERIA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 169. NIGERIA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 172. NORWAY EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. NORWAY EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 174. NORWAY EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 177. POLAND EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. POLAND EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 179. POLAND EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. QATAR EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. QATAR EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 184. QATAR EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 187. RUSSIA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. RUSSIA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 189. RUSSIA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 192. SAUDI ARABIA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. SAUDI ARABIA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 194. SAUDI ARABIA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 197. SOUTH AFRICA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. SOUTH AFRICA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH AFRICA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 202. SPAIN EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. SPAIN EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 204. SPAIN EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 207. SWEDEN EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. SWEDEN EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 209. SWEDEN EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 212. SWITZERLAND EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. SWITZERLAND EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 214. SWITZERLAND EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 217. TURKEY EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. TURKEY EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 219. TURKEY EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 222. UNITED ARAB EMIRATES EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. UNITED ARAB EMIRATES EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 224. UNITED ARAB EMIRATES EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED KINGDOM EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED KINGDOM EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED KINGDOM EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 232. EPILEPSY DRUG MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 233. EPILEPSY DRUG MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 234. EPILEPSY DRUG MARKET LICENSE & PRICING